RFA-DA-23-056: Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
Closed
This grant is closed. A newer notice from the same program is open now: Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed) (RFA-DA-26-034). Status: Closes November 18, 2027 (376 days left). It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $300,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 19, 2024.
From the official notice on Grants.gov, last changed August 18, 2022. Checked November 7, 2026.
- Award ceiling$300,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNIDA
- Median yearly award$459,424
- Typical project length3 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-DA-23-056 were run by National Institute on Drug Abuse (NIDA, 7 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-23-056 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-DA-26-034 | November 20, 2024 | Closes November 18, 2027 (376 days left) | Open |
Key dates
| Posted | August 17, 2022 |
|---|---|
| Deadline | November 19, 2024 |
| Archived by Grants.gov | December 25, 2024 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $459,424; it allows up to $300,000 per award.
- Most of the money in the 2 programs behind this notice (68% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) will support transformative research to identify and validate mechanisms, signaling pathways, and therapeutic targets, for understanding and reversing the effects of an overdose and the observed toxicities caused by acute Ultra-Potent Synthetic (UPS) opioid exposure. This FOA will also support mechanistic studies of persistent or delayed pathophysiological effects after acute exposure to UPS opioids.
Funded under RFA-DA-23-056 so far
NIH funded 7 projects under RFA-DA-23-056 in fiscal 2023 to 2026, at 7 institutions. The median yearly award was $459,424.
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, RFA-DA-26-034, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-23-056 still open?
No. It closed on November 19, 2024. A newer notice is open: RFA-DA-26-034, closes November 18, 2027 (376 days left).
Who can apply for Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)?
Closed November 19, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $300,000 each.
Who has been funded under RFA-DA-23-056?
NIH RePORTER lists 7 projects funded under RFA-DA-23-056 in fiscal 2023 to 2026, at 7 institutions. The most were at University of Chicago, University of Michigan at Ann Arbor, Jackson Laboratory.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)